Ratings
0
Nobody has rated this yet. Be the first!
Works
2
Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab
Comment on "Reduced T-dependent humoral immunity in CD20-deficient mice".
